Pharmacodynamics of bisphosphonates in arthritis

References

• Favus MJ. Bisphosphonates for osteoporosis. N. Engl. J. Med.363, 2027–2035 (2010).
   PubMed Web of Science ®Google Scholar
• Clezardin P. Bisphosphonates antitumor activity: an unravelled side of a multifaceted drug class. Bone48, 71–79 (2011).
   PubMed Web of Science ®Google Scholar
• Stresing V, Daubiné F, Benzaid I, Mönkkönen H, Clézardin P. Bisphosphonates in cancer therapy. Cancer Lett.257, 16–35 (2007).
   PubMed Web of Science ®Google Scholar
• Le Goff B, Berthelot JM, Maugars Y, Romas E. Alternative use of bisphosphonate therapy for rheumatic disease. Curr. Pharm. Des.27, 3045–3052 (2010).
   Google Scholar
• Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med.360, 679–691 (2009).
   PubMed Web of Science ®Google Scholar
• Romas E, Gillespie MT. Inflammation-induced bone loss: can it be prevented? Rheum. Dis. Clin. North. Am.32, 759–773 (2006).
   PubMed Web of Science ®Google Scholar
• Saag KG. Bisphosphonates for osteoarthritis prevention: ‘Holy Grail’ or not? Ann. Rheum. Dis.67, 1358–1359 (2008).
   PubMed Web of Science ®Google Scholar
• Cremers SC, Pillai G, Papapoulos SE. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin. Pharmacokinet.44, 551–570 (2005).
   PubMed Web of Science ®Google Scholar
• Rogers MJ, Crockett JC, Coxon FP, Mönkkönen J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone49(1), 34–41 (2011).
   PubMed Web of Science ®Google Scholar
• Lehenkari PP, Kellinsalmi M, Näpänkangas JP et al. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol. Pharmacol.61, 1255–1262 (2002).
   PubMed Web of Science ®Google Scholar
• Zhang Q, Badell IR, Schwarz EM et al. Tumor necrosis factor prevents alendronate-induced osteoclast apoptosis in vivo by stimulating Bcl-xL expression through Ets-2. Arthritis Rheum.52, 2708–2718 (2005).
   PubMedGoogle Scholar
• Sutherland KA, Rogers HL, Tosh D, Rogers MJ. RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro. Arthritis Res. Ther.11(2), R58 (2009).
   Google Scholar
• Russell RG, Xia Z, Dunford JE et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann. NY. Acad. Sci.1117, 209–257 (2007).
   PubMed Web of Science ®Google Scholar
• Szabo CM, Matsumura Y, Fukura S et al. Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents. J. Med. Chem.45, 2185–2196 (2002).
   PubMed Web of Science ®Google Scholar
• Mönkkönen H, Auriola S, Lehenkari P et al. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br. J. Pharmacol.147, 437–445 (2006).
   PubMed Web of Science ®Google Scholar
• Schett G, Teitelbaum SL. Osteoclasts and Arthritis. J. Bone Miner. Res.24, 1142–1146 (2009).
   Web of Science ®Google Scholar
• Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am. J. Pathol.152, 943–951 (1998).
   PubMed Web of Science ®Google Scholar
• Pettit AR, Ji H, von Stechow D et al.TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis: Am. J. Pathol.159, 1689–1699 (2001).
   PubMed Web of Science ®Google Scholar
• Romas E, Sims NA, Hards DK et al. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am. J. Pathol.161, 1419–1427 (2002).
   PubMed Web of Science ®Google Scholar
• Li P, Schwarz EM, O’Keefe RJ et al. Systemic tumor necrosis factor α mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor α-transgenic mice. Arthritis Rheum.50, 265–276 (2004).
   PubMed Web of Science ®Google Scholar
• Ghishan FK, Kiela PR. Advances in the understanding of mineral and bone metabolism in inflammatory bowel diseases. Am. J. Physiol. Gastrointest. Liver Physiol.300, G191–G201 (2011).
   PubMed Web of Science ®Google Scholar
• Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM. Mechanisms of TNF-α- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J. Clin. Invest.111, 821–831 (2003).
   PubMed Web of Science ®Google Scholar
• Herman S, Müller RB, Krönke G et al. Induction of osteoclast-associated receptor, a key osteoclast costimulation molecule, in rheumatoid arthritis. Arthritis Rheum.58, 3041–3050 (2008).
   PubMedGoogle Scholar
• Ma YD, Park C, Zhao H et al. Defects in osteoblast function but no changes in long-term repopulating potential of hematopoietic stem cells in a mouse chronic inflammatory arthritis model. Blood114, 4402–4410 (2009).
   PubMedGoogle Scholar
• Koch AE, Harlow LA, Haines GK et al. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J. Immunol.152, 4149–4156 (1994).
   PubMed Web of Science ®Google Scholar
• Middleton J, Americh L, Gayon R et al. Endothelial cell phenotypes in the rheumatoid synovium: activated, angiogenic, apoptotic and leaky. Arthritis Res. Ther.6, 60–72 (2004).
   PubMed Web of Science ®Google Scholar
• Choi ST, Kim JH, Seok J, Park Y, Lee S. Therapeutic effect of anti-vascular endothelial growth factor receptor I antibody in the established collagen-induced arthritis mouse model. Clin. Rheumatol.28, 333–337 (2009).
   PubMed Web of Science ®Google Scholar
• Wood J, Bonjean K, Ruetz S et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J. Pharmacol. Exp. Ther.302, 1055–1061 (2002).
   PubMed Web of Science ®Google Scholar
• Santini D, Vincenzi B, Dicuonzo G et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin. Cancer Res.2893–2897 (2003).
   PubMedGoogle Scholar
• Fournier P, Boissier S, Filleur S et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res.62, 6538–6544 (2002).
   PubMed Web of Science ®Google Scholar
• Biver E, Vieillard MH, Cortet B, Salleron J, Falgayrac G, Penel G. No anti-angiogenic effect of clinical dosing regimens of a single zoledronic acid injection in an experimental bone healing site. Bone46, 643–648. (2010).
   PubMedGoogle Scholar
• Croucher PI, De Hendrik R, Perry MJ et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J. Bone Miner. Res.18, 482–492 (2003).
   PubMed Web of Science ®Google Scholar
• Giuliani N, Pedrazzoni M, Passeri G, Girasole G. Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. Scand. J. Rheumato.27, 38–41 (1998).
   PubMed Web of Science ®Google Scholar
• Pennanen N, Lapinijoki S, Urtti A, Monkkonen J. Effect of liposomal and free bisphosphonates on the IL-1, IL-6 and TNF secretion from RAW264 cells in vitro. Pharmacol. Res.12, 916–922 (1995).
   Google Scholar
• Richards PJ, Amos N, Williams AS, Williams BD. Pro-inflammatory effects of the aminobisphosphonate ibandronate in vitro and in vivo. Rheumatology38, 984–991 (1999).
   PubMed Web of Science ®Google Scholar
• Sims NA, Green JR, Glatt M et al. Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis. Arthritis Rheum.50, 2338–2346 (2004).
   PubMed Web of Science ®Google Scholar
• Le Goff B, Soltner E, Charrier C et al. A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis. Arthritis Res. Ther.11, R185 (2009).
   PubMed Web of Science ®Google Scholar
• Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone48(4), 677–692 (2010).
   PubMedGoogle Scholar
• Thompson K, Rogers MJ. Statins prevent bisphosphonate-induced γ,δ-T-cell proliferation and activation in vitro. J. Bone Miner. Res.19, 278–288 (2004).
   PubMed Web of Science ®Google Scholar
• Srivastava T, Haney CJ, Alon US. Atorvastatin may have no effect on acute phase reaction in children after intravenous bisphosphonate infusion. J. Bone Miner. Res.24, 334–337 (2009).
   PubMedGoogle Scholar
• von Moos R, Strasser F, Gillessen S, Zaugg K. Metastatic bone pain: treatment options with an emphasis on bisphosphonates. Support Care Cancer16, 1105–1115 (2008).
   PubMed Web of Science ®Google Scholar
• Reszka AA, Rodan GA. Nitrogen-containing bisphosphonate: mechanism of action. Mini. Rev. Med. Chem.4, 711–719 (2004).
   PubMed Web of Science ®Google Scholar
• Bonabello A, Galmozzi MR, Canaparo R, Serpe L, Zara GP. Long-term analgesic effect of clodronate in rodents. Bone33, 567–574 (2003).
   PubMedGoogle Scholar
• Haugeberg G, Ørstavik RE, Kvien TK. Effects of rheumatoid arthritis on bone. Curr. Opin. Rheumatol.15, 469–475 (2003).
   PubMed Web of Science ®Google Scholar
• van Staa TP, Geusens P, Bijlsma JW, Leufkens HG, Cooper C. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum.54, 3104–3112 (2006).
   PubMed Web of Science ®Google Scholar
• Chopin F, Garnero P, le Henanff A et al. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann. Rheum. Dis.67, 353–357 (2008).
   PubMed Web of Science ®Google Scholar
• Vis M, Havaardsholm EA, Haugeberg G et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFκB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann. Rheum. Dis.65, 1495–1499 (2006).
   PubMed Web of Science ®Google Scholar
• Hoes JN, Jacobs JWG, Buttgereit F, Bijlsma JWJ. Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis. Nat. Rev. Rheumatol.6, 693–702 (2010).
   PubMed Web of Science ®Google Scholar
• Saag KG, Emkey R, Schnitzer TJ et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N. Engl. J. Med.339, 292–299 (1998).
   PubMed Web of Science ®Google Scholar
• Cohen S, Levy RM, Keller M et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum.42, 2309–2318 (1999).
   PubMed Web of Science ®Google Scholar
• Reid DM, Devogelaer JP, Saag K et al. HORIZON investigators: Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet.373, 1253–1263 (2009).
   PubMed Web of Science ®Google Scholar
• Pazianas M, Cooper C, Ebetino FH, Russell RG. Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther. Clin. Risk Manag.21, 325–343 (2010).
   Google Scholar
• Bird HA, Hill J, Sitton NG, Dixon JS, Wright V. A clinical and biochemical assessment of etidronate disodium in patients with active rheumatoid arthritis. Clin. Rheumatol.7, 91–94 (1988).
   PubMedGoogle Scholar
• Ralston SH, Hacking L, Willocks L, Bruce F, Pitkeathly DA. Clinical, biochemical, and radiographic effects of aminohydroxypropylidene bisphosphonate treatment in rheumatoid arthritis. Ann. Rheum. Dis.48, 396–399 (1989).
   PubMed Web of Science ®Google Scholar
• Maccagno A, Di Giorgio E, Roldan EJ, Caballero LE, Perez Lloret A. Double blind radiological assessment of continuous oral pamidronic acid in patients with rheumatoid arthritis. Scand. J. Rheumatol.23, 211–214 (1994).
   PubMed Web of Science ®Google Scholar
• Eggelmeijer F, Papapoulos SE, van Paassen HC, Dijkmans BA, Breedveld FC. Clinical and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis: a double blind placebo controlled study. J. Rheumatol.21, 2016–2020 (1994).
   PubMed Web of Science ®Google Scholar
• Cantatore FP, Acquista CA, Pipitone V. Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate. J. Rheumatol.26, 2318–2323 (1999).
   PubMed Web of Science ®Google Scholar
• Van Offel JF, Schuerwegh AJ, Bridts CH, Bracke PG, Stevens WJ, De Clerck LS. Influence of cyclic intravenous pamidronate on proinflammatory monocytic cytokine profiles and bone density in rheumatoid arthritis treated with low dose prednisolone and methotrexate. Clin. Exp. Rheumatol.19, 13–20 (2001).
   PubMed Web of Science ®Google Scholar
• Valleala H, Laitinen K, Pylkkänen L, Konttinen YT, Friman C. Clinical and biochemical response to single infusion of clodronate in active rheumatoid arthritis – a double blind placebo controlled study. Inflamm. Res.50, 598–601 (2001).
   PubMedGoogle Scholar
• Mazzantini M, Di Munno O, Metelli MR, Bulleri M, Giordani R. Single infusion of neridronate (6-amino-1-hydroxyhexylidene-1,1-bisphosphonate) in patients with active rheumatoid arthritis: effects on disease activity and bone resorption markers. Aging Clin. Exp. Res.14, 197–201 (2002).
   PubMed Web of Science ®Google Scholar
• Hasegawa J, Nagashima M, Yamamoto M, Nishijima T, Katsumata S, Yoshino S. Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis. J. Rheumatol.30, 474–479 (2003).
   PubMedGoogle Scholar
• Valleala H, Laasonen L, Koivula M et al. Two year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of disease. J. Rheumatol.30, 468–473 (2003).
   PubMed Web of Science ®Google Scholar
• Lodder MC, Van Pelt PA, Lems WF, Kostense PJ, Koks CHW, Dijkmans BAC. Effects of high dose IV pamidronate on disease activity and bone metabolism in patients with active RA: a randomized, double-blind, placebo-controlled trial. J. Rheumatol.30, 2080–2081 (2003).
   PubMedGoogle Scholar
• Jarrett SJ, Conaghan PG, Sloan VS et al. Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum.54, 1410–1414 (2006).
   PubMed Web of Science ®Google Scholar
• Ceponis A, Waris E, Mönkkönen J et al. Effects of low-dose, noncytotoxic,intraarticular liposomal clodronate on development of erosions and proteoglycan loss in established antigen-induced arthritis in rabbits. Arthritis Rheum.44, 1908–1916 (2001).
   PubMedGoogle Scholar
• Barrera P, Blom A, van Lent PL et al. Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. Arthritis Rheum.43, 1951–1959 (2000).
   PubMed Web of Science ®Google Scholar
• Yarom N, Yahalom R, Shoshani Y, Hamed W, Regev E, Elad S. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int.18, 1363–1370 (2007).
   PubMed Web of Science ®Google Scholar
• Grana J, Mahia IV, Meizoso MO, Vazquez T. Multiple osteonecrosis of the jaw, oral bisphosphonate therapy and refractory rheumatoid arthritis (pathological fracture associated with ONJ and BP use for osteoporosis). Clin. Exp. Rheumatol.26, 384–385 (2008).
   PubMedGoogle Scholar
• Giusti A, Hamdy NA, Papapoulos SE. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone47, 169–180 (2010).
   PubMed Web of Science ®Google Scholar
• Somford MP, Draijer FW, Thomassen BJ, Chavassieux PM, Boivin G, Papapoulos SE. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J. Bone Miner. Res.24, 1736–1740 (2009).
   PubMed Web of Science ®Google Scholar
• Soejima M, Kawaguchi Y, Hara M, Saito S, Kamatani N, Yamanaka H. Therapeutic effects of alendronate on bone erosion and atrophy in a patient with rheumatoid arthritis and hepatitis C virus infection. J. Rheumatol.35, 2284–2286 (2008).
   PubMedGoogle Scholar
• Cohen SB, Dore RK, Lane NE et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, Phase II clinical trial. Arthritis Rheum.58, 1299–1309 (2008).
   PubMed Web of Science ®Google Scholar
• Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J. Bone Miner. Res.19–26 (2011).
   PubMedGoogle Scholar